Table 1.
Participant characteristics
| Cohort | Men/women | Age (% or years) | BMI (kg/m2) | Glucose (mmol/L) | C-peptide (nmol/L) | TAG (mmol/L) | HDL-C (mmol/L) | Figures |
|---|---|---|---|---|---|---|---|---|
| HUSK | ||||||||
| Normoglycemia | 1,923/2,614 | 47.2* | 25.2 (4.7) | 5.0 (0.8) | N/A | 1.45 (0.89) | 1.33 (0.50) | Fig. 1A and B and Supplementary Fig. 1A |
| Hyperglycemia | 122/82 | 62.2* | 26.4 (4.8) | 7.5 (0.9) | N/A | 1.86 (1.14) | 1.20 (0.44) | Fig. 1A and B and Supplementary Fig. 1A |
| Type 2 diabetes | 110/91 | 82.6* | 27.2 (5.6) | 8.9 (5.3) | N/A | 2.11 (1.54) | 1.12 (0.45) | Fig. 1A and B and Supplementary Fig. 1A |
| WNOB-1 | ||||||||
| BMI 18–57 kg/m2 | 45/40 | 44 (20.5) | 34.7 (16.4) | 5.4 (0.7) | 0.90 (0.64) | 1.21 (0.71) | 1.10 (0.45) | Fig. 2A and B |
| Pre | 11/35 | 42.5 (10.3) | 40.7 (6.2) | 5.4 (1.3) | 1.18 (0.52) | 1.35 (0.64) | 0.91 (0.34) | Fig. 2A–C and Supplementary Fig. 1B |
| Post 1 year | 11/35 | 43.5 (10.3) | 27.6 (7.1) | 4.7 (0.4) | 0.58 (0.32) | 1.00 (0.64) | 1.22 (0.36) | Fig. 2C and Supplementary Fig. 1B |
| WNOB-2 | ||||||||
| Pre | 12/33 | 40.3 (15.5) | 42.9 (4.0) | 5.4 (0.9) | 1.21 (0.68) | 1.40 (1.01) | 1.10 (0.30) | Fig. 2D and Supplementary Fig. 1C |
| Post 1 week | 12/33 | 40.3 (15.5) | N/A | 5.0 (0.6) | 1.05 (0.58) | 1.62 (0.50) | 0.80 (0.30) | Fig. 2D and Supplementary Fig. 1C |
| Post 1 year | 5/10 | 40.9 (15.8) | 28.3 (5.0) | 4.7 (0.4) | 0.53 (0.19)# | 0.87 (0.57)# | 1.14 (0.18)# | Fig. 2D and Supplementary Fig. 1C |
Data are median (interquartile range) unless otherwise indicated. For medications, see research design and methods.
N/A, not available; Post 1 week, 1 week after bariatric surgery; Post 1 year, 1 year after bariatric surgery/after profound fat loss; Pre, before bariatric surgery.
*
Percentage of participants in oldest age-group. Age-groups in HUSK: 46–47 years (n = 2,510 in total) and 70–72 years (n = 2,432 in total).
#
Data available for four patients only.